Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shaomeng Wang
University of Michigan at Ann Arbor, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ascenta Therapeutics Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
See attached
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic Car
The development of safe and effective therapies for adenoid cystic carcinoma has been hindered by the lack of appropriate experimental animal models. This proposal is focused on the development and characterization a new mouse model of adenoid cystic carcinoma, and on the evaluation of novel drugs that target the oncogenic proteins MDM2 and Bcl-2 in these tumors. Our ultimate goal is to develop a mechanism-based therapy that prolongs the survival and enhances the quality of life of patients with adenoid cystic carcinoma.
Filed on August 30, 2016.
Tell us what you know about Shaomeng Wang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Shaomeng Wang”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | MedSyn Biopharm, LLC | $0 - $4,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | MedSyn Biopharm, LLC | $0 - $4,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $0 - $4,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | Ascentage Pharma Group Corporation, Ltd. | $0 - $4,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | Ascentage Pharma Group Corporation, Ltd. | $0 - $4,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $80,000 - $99,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $0 - $4,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $60,000 - $79,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | MedSyn Biopharm, LLC | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.